Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2526)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5696)
  2. Department of Medicine (5686)
  3. GSK Faculty (1659)
  4. Human Oncology and Pathogenesis Program (1158)
  5. Department of Pathology and Laboratory Medicine (1130)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (786)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (204)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (690)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5696)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting oncogenic BRAF in human cancer
    Journal Article

    Pratilas, C. A.; Xing, F.; Solit, D. B.
    Current Topics in Microbiology and Immunology (2012)

    Fulltext@MSK | Save
  • Androgen deprivation and thromboembolic events in men with prostate cancer
    Journal Article

    Ehdaie, B.; Atoria, C. L.; Gupta, A.; Feifer, A.; Lowrance, W. T.; Morris, M. J.; Scardino, P. T.; Eastham, J. A.; Elkin, E. B.
    Cancer (2012)

    Fulltext@MSK | Save
  • A pilot study comparing the sensitivity of detecting prostate associated transcripts by adna test prostate assay to cell search in whole blood from patients with castration resistant prostate cancer
    Meeting Abstract

    Samoila, A.; Wan, M.; Anand, A.; Chuang, T.; Scher, H. I.; Fleisher, M.; Danila, D. C.
    Journal of Molecular Diagnostics (2012)

    Fulltext@MSK | Save
  • Second cancer risk following radiation therapy for seminoma: A single institution retrospective study
    Meeting Abstract

    Folkert, M. R.; Zelefsky, M. J.; Fidaleo, A.; Feldman, D. R.; Bosl, G. J.; Sheinfeld, J.; Cox, B. W.; Yamada, Y.; Alektiar, K. M.; Kollmeier, M. A.
    International Journal of Radiation Oncology, Biology, Physics (2012)

    Fulltext@MSK | Save
  • Low-dose radiation to the nerve alone impairs perineural invasion independent of cancer cell death
    Meeting Abstract

    Bakst, R. L.; Lee, N.; He, S.; Chernichenko, N.; Chen, C.; Linkov, G.; Le, H.; Koutcher, J.; Vakiani, E.; Wong, R. J.
    International Journal of Radiation Oncology, Biology, Physics (2012)

    Fulltext@MSK | Save
  • Enzalutamide in prostate cancer after chemotherapy - The authors reply
    Journal Article

    Scher, H. I.; de Bono, J. S.
    New England Journal of Medicine (2012)

    Fulltext@MSK | Save
  • Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors
    Journal Article

    Mitsiades, N.; Sung, C. C.; Schultz, N.; Danila, D. C.; He, B.; Eedunuri, V. K.; Fleisher, M.; Sander, C.; Sawyers, C. L.; Scher, H. I.
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised trial
    Journal Article

    Logothetis, C. J.; Basch, E.; Molina, A.; Fizazi, K.; North, S. A.; Chi, K. N.; Jones, R. J.; Goodman, O. B.; Mainwaring, P. N.; Sternberg, C. N.; more...
    Lancet Oncology (2012)

    Fulltext@MSK | Save
  • A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer
    Journal Article

    Fury, M. G.; Sherman, E.; Lisa, D.; Agarwal, N.; Algazy, K.; Brockstein, B.; Langer, C.; Lim, D. ; Mehra, R.; Rajan, S. K.; more...
    Journal of the National Comprehensive Cancer Network (2012)

    Fulltext@MSK | Save
  • 12th Annual Meeting of the Society of Urologic Oncology (SUO) Bladder Cancer Sessions I and II summary report
    Journal Article

    Chang, S. S.; Dinney, C. P. N.; Donat, S. M.; Dahm, P.; Gore, J. L.; Lotan, Y.; Parekh, D. J.; Solit, D. B.; O'Donnell, P. H.; Feng, F. Y.; more...
    Urologic Oncology: Seminars and Original Investigations (2012)

    Fulltext@MSK | Save